Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G A Ellard

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
British Journal of Cancer|August 1, 1988
Serum placental-like alkaline phosphatase levels and nicotine intake in smokersG A Ellard, D F Tucker, Y L Pookim, et al.
The American Review of Respiratory Disease|January 1, 1984
Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosisP Gurumurthy, M S Krishnamurthy, O Nazareth, et al.
Lancet (London, England)|February 12, 1972
Pharmacology of some slow-release preparations of isoniazid of potential use in intermittent treatment of tuberculosisG A Ellard, P T Gammon, S Lakshminarayan, et al.
British Journal of Pharmacology|September 1, 1975
The penetration of dapsone, rifampicin, isoniazid and pyrazinamide into peripheral nervesB W Allen, G A Ellard, P T Gammon, et al.
Journal of Epidemiology and Community Health|June 1, 1992
Respiratory effects of lowering tar and nicotine levels of cigarettes smoked by young male middle tar smokers. II. Results of a randomised controlled trialC H Withey, A O Papacosta, A V Swan, et al.
International Journal of Antimicrobial Agents|January 1, 1994
Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various mealsS L Chan, W W Yew, J H Porter, et al.
The American Review of Respiratory Disease|June 1, 1986
The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosisG A Ellard, D R Ellard, B W Allen, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
British Journal of Cancer|August 1, 1988
Serum placental-like alkaline phosphatase levels and nicotine intake in smokersG A Ellard, D F Tucker, Y L Pookim, et al.
The American Review of Respiratory Disease|January 1, 1984
Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosisP Gurumurthy, M S Krishnamurthy, O Nazareth, et al.
Lancet (London, England)|February 12, 1972
Pharmacology of some slow-release preparations of isoniazid of potential use in intermittent treatment of tuberculosisG A Ellard, P T Gammon, S Lakshminarayan, et al.
British Journal of Pharmacology|September 1, 1975
The penetration of dapsone, rifampicin, isoniazid and pyrazinamide into peripheral nervesB W Allen, G A Ellard, P T Gammon, et al.
Journal of Epidemiology and Community Health|June 1, 1992
Respiratory effects of lowering tar and nicotine levels of cigarettes smoked by young male middle tar smokers. II. Results of a randomised controlled trialC H Withey, A O Papacosta, A V Swan, et al.
International Journal of Antimicrobial Agents|January 1, 1994
Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various mealsS L Chan, W W Yew, J H Porter, et al.
The American Review of Respiratory Disease|June 1, 1986
The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosisG A Ellard, D R Ellard, B W Allen, et al.
Pageof 9